Chromatrap, a business unit of Porvair Sciences Ltd, has announced the launch of its own range of Chromatin Immunoprecipitation (ChIP)-validated antibodies.
Building on the company’s success in the solid-state ChIP market, which underpins modern epigenetic research, the addition of ChIP-validated antibodies further enhances the high performance application solutions that Chromatrap can provide researchers.
Chromatrap Product Development Manager, Dr Amy Beynon commented “The use of high quality and specific ChIP-validated antibodies is essential for the success of a ChIP assay. The antibody must recognise and bind to native protein that is bound to DNA. Antibodies from other applications do not always work well in ChIP. That is why our team has thoroughly investigated the top ten most referenced antibodies in recent epigenetic research papers.” She added “We are pleased to be able to offer these top quality validated antibodies to our customers alongside our expanding range of kits for ChIP assays of every type. This will give our customers confidence in their protocols and their results, safe in the knowledge that a ChIP-validated antibody was at the heart of their assay”.
Chromatrap currently offers a range of ChIP kits for qPCR or sequencing and has now launched the first nine antibodies in its Validated Antibody programme which are H3, RNA pol II (S), RNA pol II (S5), H3K9me3, 5mC, AcH3, AcH4, AR and Sin3a.
Dr Beynon continued “It is our intention to expand the range as we continue to identify, source and validate antibodies for ChIP experimental use. We hope to have most of the major epigenetic marks validated over the next 12 months, for current availability please check our website at http://bit.ly/1WrrSwO for updates.”
Chromatrap validated antibodies are available in 100uL aliquots at a concentration of 1mg/ml, delivered overnight from the company’s Wrexham, UK facility to customers worldwide.